Onychomycosis (Tinea Unguium) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Onychomycosis (Tinea Unguium) - Pipeline Review, H2 2016

Onychomycosis (Tinea Unguium) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Onychomycosis (Tinea Unguium) - Pipeline Review, H2 2016
Published Jul 20, 2016
81 pages — Published Jul 20, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Onychomycosis (Tinea Unguium) - Pipeline Review, H2 2016, provides an overview of the Onychomycosis (Tinea Unguium) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Onychomycosis (Tinea Unguium), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Onychomycosis (Tinea Unguium) and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Onychomycosis (Tinea Unguium)
- The report reviews pipeline therapeutics for Onychomycosis (Tinea Unguium) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Onychomycosis (Tinea Unguium) therapeutics and enlists all their major and minor projects
- The report assesses Onychomycosis (Tinea Unguium) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Onychomycosis (Tinea Unguium)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Onychomycosis (Tinea Unguium)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devis

  
Source:
Document ID
GMDHC8285IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents25
  List of Tables51
  List of Figures61
Introduction71
  Global Markets Direct Report Coverage71
Onychomycosis (Tinea Unguium) Overview81
Therapeutics Development92
  Pipeline Products for Onychomycosis (Tinea Unguium) Overview91
  Pipeline Products for Onychomycosis (Tinea Unguium) Comparative Analysis101
Onychomycosis (Tinea Unguium) Therapeutics under Development by Companies111
Onychomycosis (Tinea Unguium) Pipeline Products Glance124
  Late Stage Products121
  Clinical Stage Products131
  Early Stage Products141
  Unknown Stage Products151
Onychomycosis (Tinea Unguium) Products under Development by Companies161
Onychomycosis (Tinea Unguium) Companies Involved in Therapeutics Development1715
  Almirall, S.A.171
  Anacor Pharmaceuticals, Inc.181
  Arno Therapeutics, Inc.191
  Blueberry Therapeutics Ltd201
  Crescita Therapeutics Inc.211
  Eisai Co., Ltd.221
  Helix BioMedix, Inc.231
  Hexima Limited241
  Meiji Seika Pharma Co., Ltd.251
  Moberg Pharma AB261
  NAL Pharmaceuticals Ltd.271
  Nihon Nohyaku Co., Ltd.281
  Novabiotics Limited291
  Novan, Inc.301
  Viamet Pharmaceuticals, Inc.311
Onychomycosis (Tinea Unguium) Therapeutics Assessment329
  Assessment by Monotherapy Products321
  Assessment by Target332
  Assessment by Mechanism of Action352
  Assessment by Route of Administration372
  Assessment by Molecule Type392
Drug Profiles4127
  AN-2718 Drug Profile411
  AR-12 Drug Profile423
  BB-0305 Drug Profile451
  Drug for Onychomycosis Drug Profile461
  ELS-160 Drug Profile471
  fosravuconazole Drug Profile482
  HB-1275 Drug Profile501
  HXP-124 Drug Profile511
  luliconazole Drug Profile523
  ME-1111 Drug Profile551
  NAL-3216 Drug Profile561
  NP-213 Drug Profile571
  SB-208 Drug Profile581
  terbinafine Drug Profile593
  terbinafine Drug Profile621
  terbinafine Drug Profile631
  VT-1161 Drug Profile644
Onychomycosis (Tinea Unguium) Dormant Projects683
Onychomycosis (Tinea Unguium) Discontinued Products711
Onychomycosis (Tinea Unguium) Product Development Milestones728
  Featured News &Press Releases721
    May 18, 2016: Moberg Pharma Announces Multiple Patent Approvals for MOB-015721
    Mar 02, 2016: Viamet Reports Positive Results from Interim Analysis of RENOVATE Phase 2b Trial of VT-1161 in Onychomycosis721
    Jan 21, 2016: Moberg Pharma is contemplating a potential bond issue, updates financial targets and provides update on MOB-015731
    Jan 07, 2016: Viamet to Present at the 3rd Annual Dermatology Summit741
    Aug 11, 2015: Nuvo Research Announces Grant of United States Patent for Topical Onychomycosis Formulation741
    Jul 15, 2015: Viamet to Present at American Podiatric Medical Association 2015 Annual Scientific Meeting751
    Mar 26, 2015: Moberg Pharma Announces Grant of EU Patent for MOB-015 Related to Topical Treatment of Onychomycosis (Nail Fungus)751
    Mar 13, 2015: MOB-015 Data To Be Presented At The 73rd Annual Meeting Of The American Academy Of Dermatology761
    Mar 10, 2015: Viamet Announces Initiation of RENOVATE Phase 2b Study of Oral VT-1161 in Onychomycosis761
    Feb 11, 2015: Moberg Pharma Announces Issue of U.S. Patent Related to MOB-015 for the Treatment of Onychomycosis771
    Sep 17, 2014: Moberg Pharma Announces Successful Results for MOB-015 in a Phase II Study for the Treatment of Onychomycosis771
    Sep 10, 2014: Data for Viamet s VT-1161 Presented at ICAAC 2014781
    Dec 13, 2013: Moberg Pharma reports positive interim results in phase II clinical study of MOB-015781
    May 27, 2013: Moberg Pharma Completes Enrollment In Phase II Clinical Trial Of MOB-015791
    Nov 07, 2012: Moberg Derma Initiates Phase II Trial With MOB-015 For Treatment Of Onychomycosis791
Appendix802
  Methodology801
  Coverage801
  Secondary Research801
  Primary Research801
  Expert Panel Validation801
  Contact Us801
  Disclaimer811

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Onychomycosis (Tinea Unguium) - Pipeline Review, H2 2016" Jul 20, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Onychomycosis-Tinea-Unguium-Pipeline-Review-H2-2016-2088-16248>
  
APA:
Global Markets Direct - Market Research. (2016). Onychomycosis (Tinea Unguium) - Pipeline Review, H2 2016 Jul 20, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Onychomycosis-Tinea-Unguium-Pipeline-Review-H2-2016-2088-16248>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.